Fraser Wright - Spark Therapeutics Insider

272 -- Germany Stock  

EUR 65.93  0.27  0.41%

Co-Founder and CTO

Dr. J. Fraser Wright Ph.D. is CoFounder and Chief Technology Officer of Spark Therapeutics Inc. From July 2013 until he joined Spark Dr. Wright served as our Chief Technology Advisor. Dr. Wright established and had been the director of the Clinical Vector Core Laboratory at CHOP from 2004 to January 2015. Dr. Wright also was a Professor at the Perelman School of Medicine at the University of Pennsylvania. Dr. Wright previously served as Director of Development and Clinical Manufacturing at Avigen Inc. from 1999 to 2004 and as scientist with Sanofi Pasteur and as scholar investigator with the Canadian blood services
Age: 56  Founder Since 2015  Ph.D    
Wright received his B.S. and Ph.D. in biochemistry from the University of Toronto.

Management Efficiency

The company has return on total asset (ROA) of (29.55) % which means that it has lost $29.55 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (60.07) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 36.22 M in total debt with debt to equity ratio (D/E) of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics has Current Ratio of 9.73 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Entity Summary

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 315 people.Spark Therapeutics (272) is traded on Frankfurt Stock Exchange in Germany. It is located in 3737 Market Street and employs 315 people.

Spark Therapeutics Leadership Team

Romuald Corbau, Executive
Carol GrevePhilips, Executive
Robert Perez, Director
Lars Ekman, Director, Ph.D
Jennifer Wellman, Founder
Fraser Wright, Founder, Ph.D
Lorris Betz, Director
Morgan Molloy, Executive
Joseph Barge, Executive
Katherine High, President, Ph.D
Elliot Sigal, Director
John Furey, COO, MBA
Vincent Milano, Director
Lota Zoth, Director
Rogerio Coelho, Executive
Guang Qu, Executive
Daniel Takefman, Executive, Ph.D
Stephen Webster, CFO, MBA
Rogerio Vivaldi, Executive
Diane Blumenthal, Executive, MBA
Jeffrey Marrazzo, CEO, MBA
Daniel Faga, Executive, MBA
Anand Mehra, Director
Linda Hearne, Executive, MBA
Paul Gil, Executive, MBA
Charles Sigal, Director
Federico Mingozzi, Executive
Steven Altschuler, Chairman
Lisa Dalton, Executive, MBA

Stock Performance Indicators

Current Sentiment - 272

Spark Therapeutics Investor Sentiment
Macroaxis portfolio users are unresponsive in their sentiment towards investing in Spark Therapeutics. What is your outlook on investing in Spark Therapeutics? Are you bullish or bearish?
50% Bullish
50% Bearish

Thematic Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Thematic Ideas
Explore Investing Ideas  
Check also Trending Equities. Please also try Fundamentals Matrix module to view fundamentals matrix and analyze how accounts are interrelated and interconnected with each other.